<DOC>
	<DOCNO>NCT01367457</DOCNO>
	<brief_summary>The principal objective study evaluate efficacy safety temsirolimus use patient Renal Cell Carcinoma Mantle Cell Lymphoma .</brief_summary>
	<brief_title>INHIBITOR : Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus</brief_title>
	<detailed_description>There sample method</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients Renal Cell Carcinoma Mantle Cell Lymphoma treat Temsirolimus per clinical practice . Patients minimum ( prespecified ) data clinical record .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>